No Data
No Data
Express News | Summary of Shareholding on May 8.
Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ): Director and Vice General Manager Zhang Lu intends to reduce shareholding by no more than 0.06%.
Gelonghui reported on May 8 that Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) announced that the company's Director and Vice General Manager, Ms. Zhang Lu, directly holds 1,800,000 shares of the company (accounting for 0.34% of the total share capital). She plans to reduce her shareholding in the company by no more than 300,000 shares (including this number) within 3 months after 15 trading days from the date of the announcement via centralized bidding trading, with the planned reduction not exceeding 0.06% of the total share capital.
Express News | Zhejiang Wolwo Bio-Pharmaceutical: The controlling Shareholder plans to reduce its Shareholding by no more than 0.86% of the total share capital through Trade.
Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ): The allogeneic mesenchymal stem cell therapy drug being researched by the subsidiary is currently in the preclinical research stage.
Glonghui on May 6th丨Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) stated on the investor interaction platform that the allogeneic mesenchymal stem cell therapeutic drug under research by its subsidiary is currently in the preclinical research stage.
Zhejiang Wolwo Bio-Pharmaceutical (300357) 2024 annual report review: New products are gradually being released, and R&D projects are continuously advancing.
Report Overview: The company's core product, dust mite drops, is steadily growing, new product, wormwood powder drops, is rapidly increasing in volume, and the product line of puncture liquid is continuously expanding. There have been multiple advancements in the R&D field, maintaining a Shareholding rating. Investment Highlights: Maintaining a Shareholding rating. Comprehensive consideration.
Zhejiang Wolwo Bio-Pharmaceutical (300357): Steady growth of dust mites and rapid increase of sweet wormwood.
The company disclosed its 2024 annual report and 2025 first quarter report, achieving a revenue of 0.925 billion yuan in 2024, a year-on-year increase of 9.10%; the net income attributable to the parent company was 0.318 billion yuan, a year-on-year increase of 2.46%, excluding non-recurring items.